Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Daptomycin Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

NCT00882557
View directory record Official record
Conditions
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Cypress, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903
View directory record Official record
Conditions
Endocarditis, Bacterial, Infective Endocarditis
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Greenville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 2, 2026, 4:12 PM EDT
Not listed No phase listed Observational

Utility Assessment of a Pharmacy-to-Dose Daptomycin

NCT05224687
View directory record Official record
Conditions
Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions
Retroactive review of patient data of those receiving a dose of daptomycin
Other
Lead sponsor
Methodist Health System
Other
Eligibility
Not listed
Enrollment
100 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NCT00261807
View directory record Official record
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Interventions
Daptomycin 6mg/kg/day
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

NCT01133600
View directory record Official record
Conditions
Diabetic Foot
Interventions
Cubicin, Vancomycin
Drug
Lead sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

NCT00102947
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
daptomycin (up to 14 days)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Torrance, California • Tampa, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 2, 2026, 4:12 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

NCT01612052
View directory record Official record
Conditions
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Antibiotic Prophylaxis
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 2, 2026, 4:12 PM EDT
Recruiting Phase 4 Interventional

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

NCT07376889
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

NCT01196169
View directory record Official record
Conditions
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Mountain Home Research & Education Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Johnson City, Tennessee • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

NCT02097953
View directory record Official record
Conditions
Drug Interactions, Pharmacokinetics
Interventions
Daptomycin, Rifampin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

NCT01191840
View directory record Official record
Conditions
Bacteremia
Interventions
Vancomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

NCT00967941
View directory record Official record
Conditions
MRSA Infections
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus

NCT00507247
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Daptomycin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 2, 2026, 4:12 PM EDT
Withdrawn Not applicable Interventional

Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

NCT00296049
View directory record Official record
Conditions
Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)

NCT00663403
View directory record Official record
Conditions
Critically Ill, Hemodialysis
Interventions
Daptomycin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

NCT00136292
View directory record Official record
Conditions
Gram-positive Bacterial Infections
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Kansas City, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 2, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

NCT00572260
View directory record Official record
Conditions
Antimicrobial Prophylaxis
Interventions
daptomycin 6 mg/kg IV
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 2, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 2, 2026, 4:12 PM EDT